Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback